PHAS News and Press, PhaseBio Pharmaceuticals Inc. From 11/15/21

Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of clinical hemostasis achieved in greater than 90% of patients ...

PhaseBio Pharmaceuticals (NASDAQ:PHAS): Q3 GAAP EPS of -$0.66 misses by $0.05. Revenue of $0.34M misses by $0.73M. Press Release For further details see: PhaseBio Pharmaceuticals EPS misses by $0.05, misses on revenue

Announced topline data from Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old Reached interim enrollment milestone for the REVERSE-IT Phase 3 trial of bentracimab Prespecified interim analysis of pivotal REVERSE-IT...

Prespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November 15th at the American Heart Association’s Scientific Sessions 2021 Guest speakers include Deepak L. Bhatt, M.D., MPH; Charles Pollack, M.D.;...

PhaseBio Pharmaceuticals (NASDAQ:PHAS) announces that its bentracimab treatment met the primary endpoint in a mid-stage trial conducted in healthy, older volunteers 50-80 years old. The Phase 2b trial is a multi-center, randomized, double-blind, placebo-controlled study with 15...

Trial achieved primary reversal endpoint in healthy, older volunteers Safety and efficacy profile of bentracimab in the Phase 2b trial consistent with previously completed Phase 1 and Phase 2a trials Interim results from REVERSE-IT Phase 3 trial to be presented on Nove...

This month is an interesting one for penny stocks and blue-chip stocks alike. It marks the official end of the Halloween season and the start of the holidays. November also kicks off the midway part of Q4. But earnings aren’t the only thing that’s going to be at the to...

NeuroBo Pharmaceuticals (NASDAQ:NRBO) +23% announces positive recommendation from independent data safety monitoring committee of phase 2/3 clinical trial of ANA001 in hospitalized patients with moderate to severe COVID-19 Jasper Therapeutics (NASDAQ:JSPR) +22% after bullish ca...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that REVERSE-IT ( R apid and Sustain E d Re VERS al of ...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally...